申请人:Sandoz, Inc.
公开号:US04096140A1
公开(公告)日:1978-06-20
Compounds of the formula ##STR1## WHEREIN R.sub.1 is hydrogen, alkyl of 1 to 6 carbon atoms or amino, R.sub.2 is hydrogen or alkyl of 1 to 6 carbon atoms, with the provisos that (1) at least one of R.sub.1 and R.sub.2 is not a tertiary alkyl group and (2) R.sub.2 is hydrogen when R.sub.1 is amino, or R.sub.1 and R.sub.2 taken together and with the nitrogen atom to which they are joined are pyrrolidino, piperidino or N'-2-hydroxyethylpiperazino, Each X' is independently alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms or halo, or two X's on adjacent carbon atoms together are methylenedioxy, and n is 0, 1, 2 or 3, And the pharmaceutically acceptable acid addition salts thereof, Are useful as anti-obesity and anti-diabetic agents. The compounds wherein R.sub.1 is alkyl and R.sub.2 is hydrogen are synthesized by a two-step synthesis from 2-alkyl-5-arylisoxazolium salts and ethylenediamine. The compounds wherein R.sub.1 and R.sub.2 are hydrogen are synthesized by cleaving the t-butyl group from the corresponding compounds wherein R.sub.1 is t-butyl and R.sub.2 is hydrogen. The compounds wherein R.sub.1 is amino are synthesized from the corresponding compounds wherein R.sub.1 is hydrogen or alkyl. All of the compounds are synthesized by reacting ammonia, a suitable amine or hydrazine with a compound of the formula ##STR2## WHEREIN R' is primary or secondary alkyl of 1 to 4 carbon atoms.
公式为 ##STR1## 的化合物,其中R.sub.1是氢、1到6个碳原子的烷基或氨基,R.sub.2是氢或1到6个碳原子的烷基,但有以下规定:(1) R.sub.1和R.sub.2中至少有一个不是三级烷基,(2) 当R.sub.1是氨基时,R.sub.2是氢,或者当R.sub.1和R.sub.2与它们连接的氮原子一起取代为吡咯烷基、哌啶烷基或N'-2-羟乙基哌嗪基时,R.sub.2是氢。每个X'独立地是1到4个碳原子的烷基、1到4个碳原子的烷氧基或卤素,或相邻碳原子上的两个X'一起是甲二氧基,n为0、1、2或3。以及其药学上可接受的酸加盐。这些化合物可用作抗肥胖和抗糖尿病药物。其中R.sub.1是烷基且R.sub.2是氢的化合物是通过从2-烷基-5-芳基异噁唑鎓盐和乙二胺的两步合成而得。其中R.sub.1和R.sub.2都是氢的化合物是通过从相应的R.sub.1为叔丁基且R.sub.2为氢的化合物中裂解叔丁基基团而得。其中R.sub.1是氨基的化合物是从相应的R.sub.1为氢或烷基的化合物中合成得到。所有这些化合物都是通过将氨、适当的胺或肼与公式为 ##STR2## 的化合物反应而合成的,其中R'是1到4个碳原子的一级或二级烷基。